Alpha Tau Medical Ltd. (DRTS) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 5.70
30Y Low5.7·High5.7
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
8.20
↑+152% vs avg
5yr avg: 3.25
30Y Low1.9·High5.2
ROE
↑
-61.0%
-6% vs avg
5yr avg: -57.5%
30Y Low-95%·High-31%
Debt/EBITDA
N/A
—
5yr avg: 0.36
30Y Low0.4·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DRTS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alpha Tau Medical Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $691M | $399M | $217M | $209M | $202M | $398M | — | — |
| Enterprise Value | $689M | $397M | $216M | $209M | $201M | $429M | — | — |
| P/E Ratio → | -14.81 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 8.20 | 5.17 | 3.46 | 2.47 | 1.91 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DRTS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | 5.70 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
DRTS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -61.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -61.0% | -61.0% | -43.2% | -30.7% | -95.3% | — | — | — |
| ROA | -44.2% | -44.2% | -32.8% | -25.6% | -41.6% | -57.3% | -21.0% | -26.8% |
| ROIC | -46.5% | -46.5% | -36.9% | 28.2% | -47.7% | -79.9% | -49.7% | — |
| ROCE | -48.7% | -48.7% | -40.5% | 33.0% | -41.8% | -31.1% | -22.8% | -26.5% |
DRTS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.20 | 0.16 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | 0.36 | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.02 | 0.01 | -0.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | 0.02 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -100.93 | -100.93 | -104.77 | 914.87 | -18.17 | -1.04 | -42.60 | — |
Net cash position: cash ($16M) exceeds total debt ($14M)
DRTS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Alpha Tau Medical Ltd.'s current ratio of 7.45x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.07x to 7.45x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.45 | 7.45 | 7.40 | 12.07 | 24.55 | 7.41 | 22.73 | 22.11 |
| Quick Ratio | 7.45 | 7.45 | 7.40 | 12.08 | 24.55 | 9.26 | 22.73 | 21.27 |
| Cash Ratio | 7.32 | 7.32 | 6.87 | 11.52 | 24.10 | 7.11 | 22.04 | 20.85 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
DRTS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alpha Tau Medical Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $81M | $70M | $69M | $64M | $41M | $40M | $68M |
Peer Comparison
Compare DRTS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DRTSYou | $691M | -14.8 | — | — | — | — | -61.0% | -46.5% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 IART | $1B | -2.0 | 13.0 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 ARAY | $35M | -18.9 | 11.0 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 MRKR | $24M | -1.8 | — | — | — | -350.7% | -144.8% | -0.0% | — |
 RLAY | $2B | -7.8 | — | — | 76.8% | -1971.6% | -41.1% | -37.3% | — |
 BLCO | $6B | -15.6 | 17.5 | — | 54.8% | 3.7% | -5.5% | 1.2% | 8.8 |
 NVS | $277B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ISRG | $161B | 57.6 | 43.6 | 64.7 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See DRTS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DRTS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DRTS vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonDRTS — Frequently Asked Questions
Quick answers to the most common questions about buying DRTS stock.
What is Alpha Tau Medical Ltd.'s P/E ratio?
Alpha Tau Medical Ltd.'s current P/E ratio is -14.8x. This places it at the 50th percentile of its historical range.
What is Alpha Tau Medical Ltd.'s ROE?
Alpha Tau Medical Ltd.'s return on equity (ROE) is -61.0%. The historical average is -57.5%.
Is DRTS stock overvalued?
Based on historical data, Alpha Tau Medical Ltd. is trading at a P/E of -14.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.